ATARA BIOTHERAPEUTICS, INC. (ATRA) Spending and interest coverage
- R&D / revenue · 12 months: Value 67.99%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 62.72%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -5.04×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 67.99% | Research and development expense / revenue. Period ending 2026-06-30. $4.21M ÷ $6.19M × 100 ≈ 67.99% |
| Stock-based compensation / revenue · 12 months | 62.72% | Share-based compensation / revenue. Period ending 2026-06-30. $3.88M ÷ $6.19M × 100 ≈ 62.72% |
| Interest coverage · 12 months | -5.04× | Operating income ÷ reported interest expense. $-14.23M ÷ $2.82M ≈ -5.04× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 4.21M USD | Research and Development Expense |
| Revenue | 6.19M USD | |
| Stock-based compensation | 3.88M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -14.23M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 2.82M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.21M | $6.19M | $3.88M | $-14.23M | $2.82M | 67.99% | 62.72% | -5.04× | Reported |
| 2026-03-31 | $10.18M | $23.14M | $6.29M | $-6.31M | $3.60M | 43.98% | 27.19% | -1.75× | Reported |
| 2025-12-31 | $37.45M | $120.77M | $9.75M | $35.86M | $3.79M | 31.00% | 8.07% | 9.46× | Reported |
| 2025-09-30 | $66.39M | $151.93M | $14.08M | $26.22M | $3.92M | 43.70% | 9.27% | 6.70× | Reported |
| 2025-06-30 | $107.39M | $188.67M | $19.28M | $8.04M | $4.19M | 56.92% | 10.22% | 1.92× | Reported |
| 2025-03-31 | $133.41M | $199.73M | $22.81M | $-13.39M | $4.48M | 66.79% | 11.42% | -2.99× | Reported |
| 2024-12-31 | $151.48M | $128.94M | $27.00M | $-83.44M | $4.62M | 117.48% | 20.94% | -18.08× | Reported |
| 2024-09-30 | $172.36M | (m) | $31.08M | $-131.20M | $4.77M | (m) | (m) | -27.48× | Reported |
| 2024-06-30 | $185.33M | (m) | $35.80M | $-179.05M | $4.99M | (m) | (m) | -35.91× | Reported |
| 2024-03-31 | $208.13M | (m) | $42.02M | $-232.24M | $5.10M | (m) | (m) | -45.52× | Reported |
| 2023-12-31 | $224.78M | (m) | $45.39M | $-276.01M | $5.29M | (m) | (m) | -52.22× | Reported |
| 2023-09-30 | $237.70M | (m) | $46.82M | $-291.58M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $250.97M | (m) | $49.70M | $-306.59M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $259.73M | (m) | $51.27M | $-267.31M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $272.53M | (m) | $53.84M | $-280.51M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $289.15M | (m) | $56.50M | $-298.38M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $289.33M | (m) | $56.24M | $-298.57M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $292.90M | (m) | $55.93M | $-350.44M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $282.00M | (m) | $53.87M | $-340.46M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $268.42M | (m) | $51.34M | $-328.76M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $257.96M | (m) | $50.83M | $-318.65M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $251.05M | (m) | $50.98M | $-312.60M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $244.65M | (m) | $51.35M | $-309.05M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $240.74M | (m) | $51.92M | $-307.05M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $234.40M | (m) | $50.82M | $-304.90M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $225.09M | (m) | $52.07M | $-302.49M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $216.10M | (m) | $51.70M | $-295.68M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $216.71M | (m) | $49.17M | $-297.80M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $206.53M | (m) | $46.27M | $-285.46M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $187.66M | (m) | $39.07M | $-262.55M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $167.46M | (m) | $33.82M | $-237.11M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $129.97M | (m) | $30.36M | $-191.10M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $107.22M | (m) | $27.11M | $-162.54M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $92.13M | (m) | $24.77M | $-137.82M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $81.21M | (m) | $23.10M | $-121.53M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $69.91M | (m) | $18.66M | $-104.48M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $68.11M | (m) | $17.93M | $-98.77M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $62.81M | (m) | $17.41M | $-90.34M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $56.51M | (m) | $16.78M | $-81.24M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $19.65M | (m) | $18.09M | $-84.26M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $8.96M | (m) | $15.06M | $-70.58M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $7.48M | (m) | $12.49M | $-66.20M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $2.00M | (m) | $10.25M | $-58.45M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | $-47.27M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | $-40.96M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | $-30.39M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | $-28.16M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | $-8.62M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |